Clinical Trial Update: Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated sequential administration of motavizumab and palivizumab during an RSV season in infants at risk for RSV infection; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Motavizumab (motavizumab)
• Synagis (palivizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or | Phase 2 | Status: COMPLETED | Results posted: 2012-12-11